Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.

PURPOSE To evaluate the association of subretinal hyperreflective material (SHRM) with visual acuity (VA), geographic atrophy (GA), and scar in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). DESIGN Prospective cohort study within a randomized clinical trial. PARTICIPANTS The 1185 CATT participants. METHODS Masked readers graded scar and GA on fundus photography and fluorescein angiography and graded SHRM on time-domain and spectral-domain (SD) optical coherence tomography (OCT) throughout 104 weeks. Measurements of SHRM height and width in the fovea, within the center 1 mm(2), or outside the center 1mm(2) were obtained on SD OCT images at 56 (n = 76) and 104 (n = 66) weeks. MAIN OUTCOME MEASURES Presence of SHRM, as well as location and size, and associations with VA, scar, and GA. RESULTS Among CATT participants, the percentage with SHRM at enrollment was 77%, decreasing to 68% at 4 weeks after treatment and to 54% at 104 weeks. At 104 weeks, scar was present more often in eyes with persistent SHRM than in eyes with SHRM that resolved (64% vs. 31%; P < 0.0001). Among eyes with detailed evaluation of SHRM at weeks 56 (n = 76) and 104 (n = 66), mean VA letter score was 73.5 (standard error [SE], 2.8), 73.1 (SE, 3.4), 65.3 (SE, 3.5), and 63.9 (SE, 3.7) when SHRM was absent, present outside the central 1 mm(2), present within the central 1 mm(2) but not the foveal center, or present at the foveal center (P = 0.02), respectively. When SHRM was present, the median maximum height under the fovea, within the central 1 mm(2) including the fovea and anywhere within the scan, was 86 μm, 120 μm, and 122 μm, respectively. Visual acuity was decreased with greater SHRM height and width (P < 0.05). CONCLUSIONS In eyes with neovascular age-related macular degeneration (AMD), SHRM is common and often persists after anti-vascular endothelial growth factor treatment. At 2 years, eyes with scar were more likely to have SHRM than other eyes. Greater SHRM dimensions were associated with worse VA. In eyes with neovascular AMD, SHRM is an important morphologic biomarker.

[1]  G. Ravera,et al.  The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. , 2005, American journal of ophthalmology.

[2]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[3]  Glenn J Jaffe,et al.  Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.

[4]  D. Woods,et al.  Mayo clinic , 2015, Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India.

[5]  D. Emerson.  Systems analyst. , 2000, Minnesota medicine.

[6]  Sandeep Saxena,et al.  Photoreceptor inner segment ellipsoid band integrity on spectral domain optical coherence tomography , 2014, Clinical ophthalmology.

[7]  Sandra S Stinnett,et al.  Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. , 2012, Ophthalmology.

[8]  G. Vrensen,et al.  Vascular endothelial growth factors and angiogenesis in eye disease , 2003, Progress in Retinal and Eye Research.

[9]  P. Keane,et al.  Relationship between Visual Acuity and Spectral Domain Optical Coherence Tomography Retinal Parameters in Neovascular Age-Related Macular Degeneration , 2013, Ophthalmologica.

[10]  P. Theodossiadis,et al.  The Significance of the External Limiting Membrane in the Recovery of Photoreceptor Layer after Successful Macular Hole Closure: A Study by Spectral Domain Optical Coherence Tomography , 2011, Ophthalmologica.

[11]  A. Tsujikawa,et al.  Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration. , 2009, American journal of ophthalmology.

[12]  Glenn J Jaffe,et al.  Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. , 2013, Ophthalmology.

[13]  G. Ying,et al.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.

[14]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[15]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[16]  Glenn J Jaffe,et al.  Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. , 2014, JAMA ophthalmology.

[17]  B. Carney.  University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514. Report for the period Oct 1986 - Sep 1988. , 1989 .

[18]  Sharon D. Solomon,et al.  Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. , 2014, The Cochrane database of systematic reviews.

[19]  Jiayan Huang,et al.  Risk of scar in the comparison of age-related macular degeneration treatments trials. , 2014, Ophthalmology.